Healthcare
Oramed Pharmaceuticals Inc.(ORMP)
Live Price
Offline$3.93
+1.29% today
1Y Change
+77.98%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $160.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +425.5%
- Dividend Yield
- 6.3%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Oramed Pharmaceuticals Inc. (ORMP) is a Healthcare stock with a market cap of $160.00M and listed on NASDAQ. The stock last traded around $3.93 and up 78.0% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +425.5%, a dividend yield of 6.3%. What stands out right now is revenue 0.0%, EPS +425.5%, free cash flow -8.6% with operating margin -754.4% and ROIC -19.1%. The dividend matters to the case here, with a current yield around 6.3%. Valuation already assumes a fairly strong business story at P/E 2.2 and price/sales 80.5. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines ORMP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-754.4% vs +19.4% peer median
P/E
Below sector median
2.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 31, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +425.5%, while operating margin sits near -754.4%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 6.3%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.1% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 31, 2026 | โ | -0.3% | +2.4% | +12.9% |
2026 Mar 26, 2026 | +25.0% | -0.3% | +3.0% | +16.0% |
2025 Nov 13, 2025 | +2925.0% | -2.9% | +0.8% | +27.9% |
Benchmark Edge
ORMP vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ORMP
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ORMP Max Drawdown
-23.89%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ORMP and SPY.
Company Overview
Oramed Pharmaceuticals Inc.
NASDAQ Capital Market
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
- Leadership
- Nadav Kidron
- IPO Date
- May 1, 2007
- Employees
- 13
- Street Address
- 1185 Avenue of the Americas
- Mailing
- New York City, NY, 10036
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 844 967 2633
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 2.2
- EV/EBITDA
- โ
- Price/Sales
- 80.5
- Price/Book
- 0.8
Growth
- Revenue
- 0.0%
- EPS
- +425.5%
- Free Cash Flow
- -8.6%
Profitability
- Gross Margin
- 0.7%
- Operating Margin
- -754.4%
- Net Margin
- 3766.2%
- ROE
- 43.1%
- ROIC
- -19.1%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 6.98
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.